Anticoagulation in Patients with Atrial High-rate Episodes Detected by Cardiac Implantable Electronic Devices


Cite item

Full Text

Abstract

Atrial high-rate episodes (AHRE) are atrial tachyarrhythmias that are identified by the use of continuous rhythm monitoring devices such as pacemakers, defibrillators, or implantable cardiac monitors. Nevertheless, the therapeutic implications of these rhythm disturbances remain uncertain. The presence of AHRE is associated with an increased risk of stroke as compared to patients who do not exhibit AHRE. The utilisation of oral anticoagulation has the ability to mitigate the likelihood of stroke occurrence in patients with AHRE. However, it is important to note that this treatment approach is also linked to a severe bleeding rate of approximately 2% per year. The stroke rate among individuals diagnosed with AHRE appears to be comparatively lower when compared to patients diagnosed with atrial fibrillation. The efficacy and safety of anticoagulation in patients with AHRE have yet to be definitively established. Further research is required to provide a comprehensive understanding of the effectiveness and safety of oral anticoagulation in individuals with AHRE.

About the authors

Michael Spartalis

3rd Department of Cardiology, Sotiria Thoracic Diseases General Hospital, National and Kapodistrian University of Athens

Author for correspondence.
Email: info@benthamscience.net

Christos Kontogiannis

Clinical Therapeutics, National and Kapodistrian University of Athens

Email: info@benthamscience.net

Eleftherios Spartalis

Laboratory of Experimental Surgery and Surgical Research ‘N.S. Christeas’, Medical School, National and Kapodistrian University of Athens

Email: info@benthamscience.net

Dimitrios Iliopoulos

Laboratory of Experimental Surgery and Surgical Research ‘N.S. Christeas’, Medical School, National and Kapodistrian University of Athens, Medical School

Email: info@benthamscience.net

Gerasimos Siasos

3rd Department of Cardiology, Sotiria Thoracic Diseases General Hospital, National and Kapodistrian University of Athens

Email: info@benthamscience.net

References

  1. Freedman B, Boriani G, Glotzer TV, Healey JS, Kirchhof P, Potpara TS. Management of atrial high-rate episodes detected by cardiac implanted electronic devices. Nat Rev Cardiol 2017; 14(12): 701-14. doi: 10.1038/nrcardio.2017.94 PMID: 28682320
  2. Lip GYH, Proietti M, Potpara T, et al. Atrial fibrillation and stroke prevention: 25 years of research at EP Europace journal. Europace 2023; 25(9): euad226. doi: 10.1093/europace/euad226 PMID: 37622590
  3. Miyazawa K, Pastori D, Martin DT, Choucair WK, Halperin JL, Lip GYH. Characteristics of patients with atrial high rate episodes detected by implanted defibrillator and resynchronization devices. Europace 2022; 24(3): 375-83. doi: 10.1093/europace/euab186 PMID: 34426836
  4. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2021; 42(5): 373-498. doi: 10.1093/eurheartj/ehaa612 PMID: 32860505
  5. Proietti M, Romiti GF, Vitolo M, et al. Epidemiology of subclinical atrial fibrillation in patients with cardiac implantable electronic devices: A systematic review and meta-regression. Eur J Intern Med 2022; 103: 84-94. doi: 10.1016/j.ejim.2022.06.023 PMID: 35817660
  6. Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012; 366(2): 120-9. doi: 10.1056/NEJMoa1105575 PMID: 22236222
  7. Boriani G, Glotzer TV, Santini M, et al. Device-detected atrial fibrillation and risk for stroke: An analysis of >10 000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices). Eur Heart J 2014; 35(8): 508-16. doi: 10.1093/eurheartj/eht491 PMID: 24334432
  8. Imberti JF, Mei DA, Vitolo M, et al. Comparing atrial fibrillation guidelines: Focus on stroke prevention, bleeding risk assessment and oral anticoagulant recommendations. Eur J Intern Med 2022; 101: 1-7. doi: 10.1016/j.ejim.2022.04.023 PMID: 35525635
  9. Wolfes J, Ellermann C, Frommeyer G, Eckardt L. Evidence-based treatment of atrial fibrillation around the globe: Comparison of the latest ESC, AHA/ACC/HRS, and CCS guidelines on the management of atrial fibrillation. Rev Cardiovasc Med 2022; 23(2): 056. doi: 10.31083/j.rcm2302056 PMID: 35229547
  10. Sgreccia D, Manicardi M, Malavasi VL, et al. Comparing outcomes in asymptomatic and symptomatic atrial fibrillation: A systematic review and meta-analysis of 81,462 patients. J Clin Med 2021; 10(17): 3979. doi: 10.3390/jcm10173979 PMID: 34501434
  11. Kirchhof P, Toennis T, Goette A, et al. Anticoagulation with edoxaban in patients with atrial high-rate episodes. N Engl J Med 2023; 389(13): 1167-79. doi: 10.1056/NEJMoa2303062 PMID: 37622677
  12. Bertaglia E, Blank B, Blomström-Lundqvist C, et al. Atrial high- rate episodes: Prevalence, stroke risk, implications for management, and clinical gaps in evidence. Europace 2019; 21(10): 1459-67. doi: 10.1093/europace/euz172 PMID: 31377792
  13. Healey JS, Lopes RD, Granger CB, et al. Apixaban for stroke prevention in subclinical atrial fibrillation. N Engl J Med 2024; 390(2): 107-17. doi: 10.1056/NEJMoa2310234 PMID: 37952132
  14. McIntyre WF, Benz AP, Becher N, et al. Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation: A study-level meta-analysis of the NOAH-AFNET 6 and ARTESiA trials. Circulation 2023. doi: 10.1161/CIRCULATIONAHA.123.067512 PMID: 37952187
  15. Rogalewski A, Kitsiou A, Kalyani M, et al. Atrial fibrillation in patients with embolic stroke of undetermined source during 3 years of pro-longed monitoring with an implantable loop recorder. Thromb Haemost 2021; 121(6): 826-33. doi: 10.1055/a-1346-2899 PMID: 33401327
  16. Vitolo M, Imberti JF, Maisano A, et al. Device-detected atrial high rate episodes and the risk of stroke/thrombo-embolism and atrial fibrillation incidence: A systematic review and meta-analysis. Eur J Intern Med 2021; 92: 100-6. doi: 10.1016/j.ejim.2021.05.038 PMID: 34154879
  17. Boriani G, Glotzer TV, Ziegler PD, et al. Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden. Heart Rhythm 2018; 15(3): 376-83. doi: 10.1016/j.hrthm.2017.11.007 PMID: 29122724
  18. Kalarus Z, Mairesse GH, Sokal A, et al. Searching for atrial fibrillation: Looking harder, looking longer, and in increasingly sophisticated ways. An EHRA position paper. Europace 2023; 25(1): 185-98. doi: 10.1093/europace/euac144 PMID: 36256580
  19. Proietti M. Natural history of ‘silent’ atrial fibrillation from subclinical to asymptomatic: State of the art and need for research. Eur J Intern Med 2023; 107: 27-9. doi: 10.1016/j.ejim.2022.11.015 PMID: 36404262
  20. Savelieva I, Fumagalli S, Kenny RA, et al. EHRA expert consensus document on the management of arrhythmias in frailty syndrome, endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace 2023; 25(4): 1249-76. doi: 10.1093/europace/euac123 PMID: 37061780
  21. Boriani G, Pettorelli D. Atrial fibrillation burden and atrial fibrillation type: Clinical significance and impact on the risk of stroke and decision making for long-term anticoagulation. Vascul Pharmacol 2016; 83: 26-35. doi: 10.1016/j.vph.2016.03.006 PMID: 27196706
  22. Boriani G, Healey JS, Schnabel RB, et al. Oral anticoagulation for subclinical atrial tachyarrhythmias detected by implantable cardiac devices: An international survey of the AF-SCREEN group. Int J Cardiol 2019; 296: 65-70. doi: 10.1016/j.ijcard.2019.07.039 PMID: 31327519
  23. Imberti JF, Tosetti A, Mei DA, Maisano A, Boriani G. Remote monitoring and telemedicine in heart failure: Implementation and benefits. Curr Cardiol Rep 2021; 23(6): 55. doi: 10.1007/s11886-021-01487-2 PMID: 33959819
  24. Ahmed FZ, Sammut-Powell C, Kwok CS, et al. Remote monitoring data from cardiac implantable electronic devices predicts all- cause mortality. Europace 2022; 24(2): 245-55. doi: 10.1093/europace/euab160 PMID: 34601572
  25. Boriani G, Imberti JF, Bonini N, et al. Remote multiparametric monitoring and management of heart failure patients through cardiac implantable electronic devices. Eur J Intern Med 2023; 115: 1-9. doi: 10.1016/j.ejim.2023.04.011 PMID: 37076404
  26. Wan D, Andrade J, Laksman Z. Thromboembolic risk stratification in atrial fibrillation-beyond clinical risk scores. Rev Cardiovasc Med 2021; 22(2): 353-63. doi: 10.31083/j.rcm2202042 PMID: 34258903
  27. Malavasi VL, Fantecchi E, Tordoni V, et al. Atrial fibrillation pattern and factors affecting the progression to permanent atrial fibrillation. Intern Emerg Med 2021; 16(5): 1131-40. doi: 10.1007/s11739-020-02551-5 PMID: 33161524
  28. Ding WY, Proietti M, Boriani G, et al. Clinical utility and prognostic implications of the novel 4S-AF scheme to characterize and evaluate patients with atrial fibrillation: A report from ESC-EHRA EORP-AF long-term general registry. Europace 2022; 24(5): 721-8. doi: 10.1093/europace/euab280 PMID: 35446354

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers